Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IGC AD1 · 1 trial · 1 indication
Evaluate safety and tolerability of IGC AD1 10 participants will be administered the investigational drug and two will be administered placebo. Incidence of treatment emergent adverse events will be assessed to determine safety and tolerability of IGC-AD1.
| Arm | Type | Description |
|---|---|---|
| Active | ACTIVE_COMPARATOR | IGC AD1 |
| Placebo | PLACEBO_COMPARATOR | IGC AD1 Placebo |
| Name | Type | Description |
|---|---|---|
| IGC AD1 | DRUG | IGC AD1 oral Solution |
| Placebo | DRUG | Placebo of IGC AD1 oral Solution |
Inclusion Criteria: 1. Patient and/or study partner (relative) must provide a signed and dated Informed Consent form prior to any study procedures which will be discussed with the Study Coordinator. 2. Provision of a letter from the Neurologist/Psychiatrist/Internal Medicine Physician certifying th...
IGC AD1 is an investigational small molecule being developed for the treatment of dementia of Alzheimer type. It is intended for patients with dementia due to Alzheimer's disease. The drug is currently in clinical development and has not been approved by regulatory authorities.
IGC AD1 is being developed by IGC Pharma, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol IGC. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for Alzheimer's disease dementia.
IGC AD1 is in Phase 1 clinical development. A Phase 1 trial has been completed, which was a randomized, double-blind, placebo-controlled study involving 12 participants. The drug remains investigational and is not yet approved for commercial use.
IGC AD1 has one completed clinical trial registered under NCT04749563, titled 'Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease'. This Phase 1 study was conducted in Puerto Rico with 12 participants aged 60 years and older, and it was randomized, double-blind, and placebo-controlled.
Yes, IGC AD1 is the same drug as IGC-AD1. The compound is referred to by both names in clinical and regulatory contexts. The clinical trial NCT04749563 uses the name IGC-AD1, while the drug is also commonly known as IGC AD1 in other references.